Cetuximab for the Treatment of Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR. METHODS: From December 2003 to August 2005, 572 patients who had colorectal cancer expressing immunohistochemically detectable EGFR and who had been previously treated with a fluoropyrimidine, irinotecan, and oxaliplatin or had contraindications to treatment with these drugs underwent randomization to an initial dose of 400 mg of cetuximab per square meter of body-surface area followed by a weekly infusion of 250 mg per square meter plus best supportive care (287 patients) or best supportive care alone (285 patients). The primary end point was overall survival. RESULTS: In comparison with best supportive care alone, cetuximab treatment was associated with a significant improvement in overall survival (hazard ratio for death, 0.77; 95% confidence interval [CI], 0.64 to 0.92; P=0.005) and in progression-free survival (hazard ratio for disease progression or death, 0.68; 95% CI, 0.57 to 0.80; P<0.001). These benefits were robust after adjustment in a multivariable Cox proportional-hazards model. The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group assigned to supportive care alone. Partial responses occurred in 23 patients (8.0%) in the cetuximab group but in none in the group assigned to supportive care alone (P<0.001); the disease was stable in an additional 31.4% of patients assigned to cetuximab and in 10.9% of patients assigned to supportive care alone (P<0.001). Quality of life was better preserved in the cetuximab group, with less deterioration in physical function and global health status scores (both P<0.05). Cetuximab treatment was associated with a characteristic rash; a rash of grade 2 or higher was strongly associated with improved survival (hazard ratio for death, 0.33; 95% CI, 0.22 to 0.50; P<0.001). The incidence of any adverse event of grade 3 or higher was 78.5% in the cetuximab group and 59.1% in the group assigned to supportive care alone (P<0.001). CONCLUSIONS: Cetuximab improves overall survival and progression-free survival and preserves quality-of-life measures in patients with colorectal cancer in whom other treatments have failed. (ClinicalTrials.gov number, NCT00079066 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cetuximab is a chimeric (mouse/human) monoclonal IgG1 antibody developed to bind the extracellular EGFR domain that blocks dimerization and ligand-induced signaling of the EGFR pathway [14].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
In the citing paper
“Patients who received cetuximab had a 6.1-month median survival compared with 4.6 months among individuals in the best supportive care group.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationGoldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Research works printed but not linked: 3
- Mellstedt H, 2003, Drugs Today (Barc), 39, 1
- Eng C, 2007, J Clin Oncol, 25, 18s
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
Cited by
Items 501–600 of 1,001
Ciracì, P., Studiale, V., Taravella, A., Antoniotti, C., & Cremolini, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00965-0 · Cited by 53
Bowles, D. W., Kochenderfer, M., Cohn, A., Sideris, L., Nguyen, N., Cline-Burkhardt, V., Schnadig, I., Choi, M., Nabell, L., Chaudhry, A., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.03.004 · Cited by 42
“Median number of prior systemic therapies mean/range 3 (1-8) 3 (1-12) 0.”
BackgroundJeong, J. H., Kim, J., Hong, Y. S., Kim, D., Kim, J. E., Kim, S. Y., Kim, K., Yoon, Y., Kim, D., Chun, S., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.005 · Cited by 49
Lin, C., Yang, S., Peng, C., & Shieh, M. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b13431 · Cited by 43
Elevated Methionine Flux Drives Pyroptosis Evasion in Persister Cancer Cells
El-Kenawi, A., Berglund, A., Estrella, V. C., Zhang, Y., Liu, M., Putney, R. M., Yoder, S., Johnson, J., Brown, J. S., & Gatenby, R. A. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1002 · Cited by 47
Yamada, T., Takeuchi, S., Kita, K., Bando, H., Nakamura, T., Matsumoto, K., & Yano, S. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182398e69 · Cited by 48
EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects
Pérez, R., Moreno, E., Garrido, G., & Crombet, T. (2011) · Cancers · doi:10.3390/cancers3022014 · Cited by 45
Current and advancing treatments for metastatic colorectal cancer
Sanz‐García, E., Grasselli, J., Argilés, G., Elez, M. E., & Tabernero, J. M. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1108405 · Cited by 42
Bouché, O., Maindrault‐Gœbel, F., Ducreux, M. P., Lledo, G., André, T., Stopfer, P., Amellal, N., Merger, M., & de Gramont, A. (2011) · PubMed · Cited by 44
Shao, Y., Hsu, C.-H., & Cheng, A.-L. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i36.10336 · Cited by 44
Matada, G. S. P., Dhiwar, P. S., Abbas, N., Singh, E., Ghara, A., Das, A., & Bhargava, S. V. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1877823 · Cited by 47
Chen, P., Wang, L., Li, H., LIU, B., & Zou, Z. (2013) · Oncology Letters · doi:10.3892/ol.2013.1301 · Cited by 42
Treatment Advances in Liver-Limited Metastatic Colorectal Cancer
Alberts, S. R., & Poston, G. J. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.06.008 · Cited by 41
Evolution of systemic therapy for advanced pancreatic cancer
Renouf, D. J., & Moore, M. J. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.21 · Cited by 44
Self-citationTan, K. F., In, L. L. A., & Kumar, P. V. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00202 · Cited by 49
Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
Ríos-Hoyo, A., Monzonís, X., Vidal, J., Linares, J., & Montagut, C. O. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1398419 · Cited by 46
“Subsequently, the frontline pivotal randomized trials that tested anti-EGFR therapies in combination with chemotherapy doublets (Jonker et al., 2007; Amado et al., 2008; Karapetis et al., 2008), showed a bene fi t in ORR (46.9% – 58%), mPFS (9.9 – 12 months), and mOS (19.8 – 24.9 months) (Bokemeyer…”
BackgroundInfluentialA phase 1 study of ABT-806 in subjects with advanced solid tumors
Cleary, J. M., Reardon, D. A., Azad, N. S., Gandhi, L., Shapiro, G. I., Chaves, J. M., Pedersen, M., Ansell, P. J., Ames, W., Xiong, H., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0234-6 · Cited by 41
Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer
Della Corte, C., Fasano, M., Papaccio, F., Ciardiello, F., & Morgillo, F. (2014) · Biomedicines · doi:10.3390/biomedicines2040345 · Cited by 41
Odom, D. M., Barber, B., Bennett, L., Peeters, M., Zhao, Z., Kaye, J. A., Wolf, M., & Wiezorek, J. S. (2010) · International Journal of Colorectal Disease · doi:10.1007/s00384-010-1112-5 · Cited by 41
Jatoi, A., & Nguyen, P. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0149 · Cited by 40
Li, W., Qiu, T., Ling, Y., Guo, L., Li, L., & Ying, J. (2015) · Oncotarget · doi:10.18632/oncotarget.5551 · Cited by 40
Current Tissue Molecular Markers in Colorectal Cancer: A Literature Review
Peluso, G., Incollingo, P., Calogero, A., Tammaro, V., Rupealta, N., Chiacchio, G., Sotelo, M. L. S., Minieri, G., Pisani, A., Riccio, E., et al. (2017) · BioMed Research International · doi:10.1155/2017/2605628 · Cited by 46
Advances in the Treatment of Metastatic Colorectal Cancer
Kurkjian, C. D., & Kummar, S. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181907ed9 · Cited by 43
Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review
Hoag, J. B., Azizi, A., Doherty, T. J., Lu, J. L., Willis, R. E., & Lund, M. E. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-113 · Cited by 42
Takakura, Y., Ikeda, S., Yoshimitsu, M., Hinoi, T., Sumitani, D., Takeda, H., Kawaguchi, Y., Shimomura, M., Tokunaga, M., Okajima, M., et al. (2009) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-7-74 · Cited by 42
Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer
Kasi, P. M., Afable, M. G., Herting, C. J., Lukanowski, M., & Jin, Z. (2023) · The Oncologist · doi:10.1093/oncolo/oyad262 · Cited by 47
Jiang, Y., Cao, H., Deng, H., Guan, L., Langthasa, J., Colburg, D. R. C., Melemenidis, S., Cotton, R. M., Aleman, J., Wang, X., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02448-0 · Cited by 48
Alexander, H. R., Bartlett, D. L., Libutti, S. K., Pingpank, J. F., Fraker, D. L., Royal, R. E., Steinberg, S. M., Helsabeck, C. B., & Beresneva, T. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0482-9 · Cited by 40
Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer
Sameen, S., Barbuti, R., Milazzo, P., Cerone, A., Re, M. D., & Danesi, R. (2015) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2015.10.019 · Cited by 42
Pinta, F., Ponzetti, A., Spadi, R., Fanchini, L., Zanini, M., Mecca, C., Sonetto, C., Ciuffreda, L., & Racca, P. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.10.001 · Cited by 41
Liu, G., Tu, D., Lewis, M. E., Cheng, D., Sullivan, L. A., Chen, Z., Morgen, E. K., Simes, J. R., Price, T. J., Tebbutt, N. C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0414 · Cited by 42
Self-citationGouverneur, A., Salvo, F., Berdaï, D., Moore, N. D., Fourrier‐Réglat, A., & Noïze, P. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.08.001 · Cited by 43
Cheng, S., Qureshi, M. I., Pullenayegum, E., Haynes, A. E., & Chan, K. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000225 · Cited by 40
Peeters, M., Price, T. J., Boedigheimer, M. J., Kim, T. W., Ruff, P., Gibbs, P., Thomas, A., Demonty, G., Hool, K., & Ang, A. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2072 · Cited by 40
Self-citationSignalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy
Ramsay, A., & Leung, H. Y. (2009) · Clinical Science · doi:10.1042/cs20080391 · Cited by 54
KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal Cancer
Jimeno, A., Messersmith, W. A., Hirsch, F. R., Franklin, W. A., & Eckhardt, S. G. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e31819e3202 · Cited by 40
Milenic, D. E., Baidoo, K. E., Kim, Y., & Brechbiel, M. W. (2015) · mAbs · doi:10.4161/19420862.2014.985160 · Cited by 40
Shin, B. K. (2011) · Oncology Reports · doi:10.3892/or.2011.1545 · Cited by 47
“Cetuximab, the recombinant monoclonal antibody against the extracellular domain of EGFR, has improved the survival in patients whose tumors were resistant to previous conventional chemotherapeutic agents (6,7).”
Backgroundegfr Overexpression in Squamous Cell Carcinoma of the Penis
Lavens, N., Gupta, R., & Wood, L. A. (2010) · Current Oncology · doi:10.3747/co.v17i1.471 · Cited by 43
Targeted Therapies: The Rare Cancer Paradigm
Pierotti, M. A., Negri, T., Tamborini, E., Perrone, F., Pricl, S., & Pilotti, S. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2009.10.003 · Cited by 42
Current and future biomarkers in the treatment of colorectal cancer
Cuyle, P.-J. A., & Prenen, H. (2016) · Acta Clinica Belgica · doi:10.1080/17843286.2016.1262996 · Cited by 42
Hepatic metastasis from colorectal cancer
Aloia, T. A., & Vauthey, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-34062-5.00092-3 · Cited by 39
Angelis, A., Montibeller, G., Hochhauser, D., & Kanavos, P. G. (2017) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-017-0524-3 · Cited by 44
Yu, Z., Dee, E. C., Bach, D. Q., Mostaghimi, A., & LeBoeuf, N. R. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.1795 · Cited by 39
Kim, B., Park, Y. S., Sung, J. S., Lee, J. W., Lee, S. B., & Kim, Y. H. (2020) · Cancer Medicine · doi:10.1002/cam4.3635 · Cited by 41
Baas, J. M., Krens, L. L., ten Tije, A. J., Erdkamp, F., van Wezel, T., Morreau, H., Gelderblom, H., & Guchelaar, H. J. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0285-8 · Cited by 38
Sato, K., Shin, M., Sakimura, A., Zhou, Y., Tanaka, T., Kawanishi, M., Kawasaki, Y., Yokoyama, S., Koizumi, K., Saiki, I., et al. (2013) · Cancer Science · doi:10.1111/cas.12225 · Cited by 40
Izar, B., Rotow, J. K., Gainor, J. F., Clark, J. W., & Chabner, B. A. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007807 · Cited by 40
Cheung, A., Chenoweth, A. M., Johansson, A., Laddach, R., Guppy, N., Trendell, J., Esapa, B., Mavousian, A., Navarro‐Llinas, B., Haider, S. A., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3110 · Cited by 39
Toxicogenomics and Cancer Susceptibility: Advances with Next-Generation Sequencing
Ning, B., Su, Z., Mei, N., Hong, H., Deng, H., Shi, L. M., Fuscoe, J. C., & Tolleson, W. H. (2014) · Journal of Environmental Science and Health Part C · doi:10.1080/10590501.2014.907460 · Cited by 40
Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis.
Mariani, P., Lae, M. E., Degeorges, A., Cacheux, W., Lappartient, E., Margogne, A., Pierga, J., Girre, V., Mignot, L., Falcou, M. C., et al. (2010) · PubMed · Cited by 40
Bar‐Ad, V., Zhang, Q., Harari, P. M., Axelrod, R. S., Rosenthal, D. I., Trotti, A., Jones, C. U., Garden, A. S., Song, G., Foote, R. L., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.03.011 · Cited by 37
Kasi, P. M., & Grothey, A. F. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000195 · Cited by 41
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
Cutsem, E. V., & Geboes, K. (2007) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2007.10.020 · Cited by 41
Targeting the epidermal growth factor receptor in solid tumors: focus on safety
Lucchini, E., Pilotto, S., Spada, E. L., Melisi, D., Bria, E., & Tortora, G. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.904283 · Cited by 40
Colon, Rectal, and Anal Cancers
Wilkes, G. M., & Hartshorn, K. L. (2009) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2008.10.003 · Cited by 45
Colorectal cancer in Chinese patients: current and emerging treatment options
Ma, B. B. Y., & Li, L. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s48409 · Cited by 36
Cetuximab in metastatic colorectal cancer
Broadbridge, V. T., Karapetis, C. S., & Price, T. J. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.25 · Cited by 39
Self-citationShankaran, V., Ortendahl, J. D., Purdum, A., Bolinder, B., Anene, A. M., Sun, G. H., & Bentley, T. G. K. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000231 · Cited by 40
Shankaran, V., Obel, J. C., & Benson, A. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0221 · Cited by 38
Targeting Cancer Resistance via Multifunctional Gold Nanoparticles
Pedrosa, P., Corvo, M. L., Ferreira-Silva, M., Martins, P. H. D. F., Carvalheiro, M. C., Costa, P. M., Martins, C., Martins, L. M. D. R. S., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215510 · Cited by 39
Kasper, S., Breitenbuecher, F., Reis, H., Brandau, S., Worm, K., Köhler, J., Paul, A., Trarbach, T., Schmid, K. W., & Schuler, M. (2013) · Oncogene · doi:10.1038/onc.2012.302 · Cited by 35
Colorectal cancer and therapy response: a focus on the main mechanisms involved
Tirendi, S., Marengo, B., Domenicotti, C., Bassi, A. M., Almonti, V., & Vernazza, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1208140 · Cited by 42
“Additionally, anti-EGFR can be used alone in chemo-refractory patients with advanced CRC (76).”
BackgroundPRMT1 in human neoplasm: cancer biology and potential therapeutic target
Shen, S., Zhou, H., Xiao, Z., Zhan, S., Tuo, Y., Chen, D., Pang, X., Wang, Y., & Wang, J. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01506-z · Cited by 38
Townsend, A. R., Bishnoi, S. K., Broadbridge, V. T., Beeke, C., Karapetis, C. S., Jain, K., Luke, C., Padbury, R., & Price, T. J. (2012) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31823fe40e · Cited by 35
Self-citationRAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial
Sclafani, F., de Castro, D. G., Cunningham, D., Wilson, S. H., Peckitt, C., Giralt, J., Glimelius, B. L. G., Roselló, S., Wotherspoon, A. C., Brown, G. M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.02.002 · Cited by 38
“Given as single agents or in combination with irinotecan, these drugs represent a standard treatment option for patients with KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) who have previously progressed to oxaliplatin- and irinotecan-based chemotherapy [3–7].”
BackgroundMusella, V., Pietrantonio, F., Buduo, E. D., Iacovelli, R., Martinetti, A., Sottotetti, E., Bossi, I. E., Maggi, C., Bartolomeo, M. D., de Braud, F., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29493 · Cited by 35
Definitions and statistical properties of master protocols for personalized medicine in oncology
Renfro, L. A., & Mandrekar, S. J. (2017) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2017.1372778 · Cited by 39
Hsieh, M., Wu, C., Chen, C.-W. D., Shi, C., Huang, W., & Kuan, F. (2018) · Scientific Reports · doi:10.1038/s41598-018-19835-8 · Cited by 38
The anti‐metastatic effect of ginsenoside Rb2 in colorectal cancer in an EGFR/SOX2‐dependent manner
Phi, L. T., Wijaya, Y. T., Sari, I. N., Yang, Y., Lee, Y. K., & Kwon, H. Y. (2018) · Cancer Medicine · doi:10.1002/cam4.1800 · Cited by 35
Cleary, J. M., Calvo, E., Moreno, V., Juric, D., Shapiro, G. I., Vanderwal, C. A., Hu, B., Gifford, M., Barch, D., Roberts-Rapp, L. A., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00908-3 · Cited by 39
Wang, X., Luo, X., Tian, Y., Wu, T., Weng, J., Li, Z., Feng, Y., & Huang, X. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00022 · Cited by 38
Pancreatic Cancer: Medical Management (Novel Chemotherapeutics)
Páez, D., LaBonte, M. J., & Lenz, H. (2012) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2011.12.004 · Cited by 40
Satoh, T., Gemma, A., Kudoh, S., Sakai, F., Yamaguchi, K., Watanabe, T., Ishiguro, M., Inoshiri, S., Izawa, M., Sugihara, K., et al. (2014) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyu128 · Cited by 35
Tahara, M., Shirao, K., Boku, N., Yamaguchi, K., Komatsu, Y., Inaba, Y., Arai, T., Mizunuma, N., Satoh, T., Takiuchi, H., et al. (2008) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyn102 · Cited by 36
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015
Aranda, E., Aparicio, J., Alonso, V., García‐Albéniz, X., Alfonso, P. G., Salazar, R., Valladares, M., Vera, R., Viéitez, J. M., & García‐Carbonero, R. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1434-4 · Cited by 40
Best supportive care in clinical trials: review of the inconsistency in control arm design
Nipp, R. D., Currow, D. C., Cherny, N. I., Strasser, F., Abernethy, A. P., & Zafar, S. Y. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.192 · Cited by 34
Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
Sakai, K., Tsurutani, J., Yamanaka, T., Yoneshige, A., Ito, A., Togashi, Y., Velasco, M. A. D., Terashima, M., Fujita, Y., Tomida, S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121891 · Cited by 37
A hazard ratio was estimated by a ratio of median survival times, but with considerable uncertainty
Cortés, J., González, J. A., Campbell, M. J., & Cobo, E. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2014.05.017 · Cited by 36
The role of personalized medicine in metastatic colorectal cancer: an evolving landscape
Moorcraft, S. Y., Smyth, E. C., & Cunningham, D. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13491797 · Cited by 40
Gajate, P., Sastre, J., Bando, I., Alonso, T., Cillero, L., Sanz‐Ortega, J., Caldés, T., & Díaz‐Rubio, E. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2012.02.003 · Cited by 39
Personalized Colon Cancer Care in 2010
Catenacci, D. V. T., Kozloff, M. F., Kindler, H. L., & Polite, B. N. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.01.001 · Cited by 41
Kasuga, A., Ishii, H., Ozaka, M., Matsusaka, S., Chìn, K., Mizunuma, N., Yukisawa, S., Matsueda, K., & Furuse, J. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys168 · Cited by 35
Tang, P. A., Hay, A. E., O’Callaghan, C. J., Mittmann, N., Chambers, C. R., Pater, J. L., & Leighl, N. B. (2016) · Current Oncology · doi:10.3747/co.23.2861 · Cited by 36
Self-citationJoseph, K. J., AlKaabi, K., Warkentin, H., Ghosh, S., Jha, N., Smylie, M., & Walker, J. W. T. (2018) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.12842 · Cited by 34
“Cetuximab is a chimeric (mouse/human) monoclonal antibody EGFR inhibitor currently used for the treatment of metastatic colorectal cancer and head and neck cancer.(5,12,13) Given the relative paucity of data to guide decision-making for patients with cSCC, and in recognition of the oncogenic potential of EGFR in cSCC,…”
MethodCancer-induced inflammation and inflammation-induced cancer in colon: a role for S1P lyase
Schwiebs, A., Juan, M. H. S., Schmidt, K. G., Wiercinska, E., Anlauf, M., Ottenlinger, F. M., Thomas, D., Elwakeel, E., Weigert, A., Farin, H. F., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0758-x · Cited by 37
Pignata, S., Scambia, G., Lorusso, D., Giorgi, U. D., Nicoletto, M. O., Lauria, R., Mosconi, A. M., Sacco, C. S. P., Omarini, C., Tagliaferri, P., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.03.260 · Cited by 34
DCLK1 integrates induction of TRIB3, EMT, drug resistance and poor prognosis in colorectal cancer
Makino, S., Takahashi, H., Okuzaki, D., Miyoshi, N., Haraguchi, N., Hata, T., Matsuda, C., Yamamoto, H., Mizushima, T., Mori, M., et al. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz157 · Cited by 36
Lee, K., Lee, K.-F., Tung, S., Huang, W., Lee, L., Chen, W.-P., Chen, C., Teng, C., Shen, C., Hsieh, M., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01174 · Cited by 34
Iwama, T., Fujiya, M., Konishi, H., Tanaka, H., Murakami, Y., Kunogi, T., Sasaki, T., Takahashi, K., Ando, K., Ueno, N., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-020-01723-9 · Cited by 34
A synopsis of modern - day colorectal cancer: Where we stand
Ranasinghe, R., Mathai, M. L., & Zulli, A. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188699 · Cited by 40
The long road to colorectal cancer therapy: Searching for the right signals
Hollande, F., Pannequin, J., & BRESSION, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2009.01.002 · Cited by 45
“These trials, which led to the DA approval of cetuximab in February 2004, already suggested hat positive response to cetuximabwas restricted to patients with ild-type KRAS tumors (Jonker et al., 2007; Van Cutsem et al., 007a, 2009; Bardelli and Siena, 2010).”
BackgroundIntegration of panitumumab into the treatment of colorectal cancer
Grávalos, C., Cassinello, J., Alfonso, P. G., & Jimeno, A. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.06.005 · Cited by 35
Poulin-Costello, M., Azoulay, L., Cutsem, E. V., Peeters, M., Siena, S., & Wolf, M. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0271-z · Cited by 37
Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review
DeStefanis, R. A., Kratz, J. D., Emmerich, P. B., & Deming, D. A. (2019) · Current Colorectal Cancer Reports · doi:10.1007/s11888-019-00430-6 · Cited by 41
Huang, F., Xu, L.-A., & Khambata-Ford, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1135 · Cited by 33
Impact of KRAS Mutations on Management of Colorectal Carcinoma
Sullivan, K. M., & Kozuch, P. S. (2011) · Pathology Research International · doi:10.4061/2011/219309 · Cited by 40
Khan, S. A., Zeng, Z., Shia, J., & Paty, P. B. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0166-2 · Cited by 34
Singh, H., Li, Y. Y., Spurr, L. F., Shinagare, A. B., Abhyankar, R., Reilly, E., Brais, L. K., Nag, A., Ducar, M. D., Thorner, A. R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4073 · Cited by 35
Statin Treatment as a Targeted Therapy for APC-Mutated Colorectal Cancer
Shailes, H., Tse, W. Y., Freitas, M. O., Silver, A., & Martin, S. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.880552 · Cited by 34
“Targeted therapies including cetuximab, which targets the epidermal growth factor receptor (EGFR), are currently approved for treatment of CRC (16).”
Background
Metadata
- Authors
- Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., Tebbutt, N. C., van Hazel, G., Wierzbicki, R., Langer, C., & Moore, M. J.
- Affiliations
- University of Ottawa (CA)
- Flinders Medical Centre (AU)
- The University of Melbourne (AU)
- Queen's University (CA)
- Cross Cancer Institute (CA)
- Sunnybrook Health Science Centre (CA)
- St. Boniface Hospital (CA)
- Queen Elizabeth Hospital (AU)
- The University of Sydney (AU)
- Austin Health (AU)
- Lakeridge Health (CA)
- Bristol-Myers Squibb (United States) (US)
- Princess Margaret Cancer Centre (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2040-2048
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115790682
- Cited by
- 1,904
- References
- 20
- Citations by year
- 2026: 23 · 2025: 47 · 2024: 56 · 2023: 60 · 2022: 62 · 2021: 63 · 2020: 87 · 2019: 82 · 2018: 84 · 2017: 101 · 2016: 110 · 2015: 133 · 2014: 143 · 2013: 150 · 2012: 153
- FWCI
- 68.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- cetuximab, colorectal cancer, epidermal growth factor receptor, EGFR-positive tumors, monoclonal antibody therapy, best supportive care, overall survival, progression-free survival, rash, quality of life, adverse events, irinotecan, oxaliplatin, fluoropyrimidine
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Exanthema, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Colorectal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.